A randomized double-blind placebo-controlled study of ALPN-101 in systemic lupus erythematosus.

Brief description of study

Lupus is a disease that occurs when your body's immune system is active in a way that can injure your own healthy tissues and organs. There is no cure for lupus, but most patients receive treatments to help reduce symptoms and reduce or prevent damage to internal organs. Current treatments may be helpful or partly helpful in many cases of lupus. This study is being done to determine if an investigational drug, ALPN-101, is safe and helpful in treating lupus when used in combination with standard lupus medications you may already be using. Your study doctor can talk to you about standard lupus medications and answer any questions you may have. ALPN101 is considered investigational since it is still being studied and is not approved by the United States Food and Drug Administration (FDA) for lupus or any other disorder.

Clinical Study Identifier: s20-01776
ClinicalTrials.gov Identifier: NCT04835441
Principal Investigator: David H. Goddard.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.